|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12...56789101112131415...156157» |
- | Trial primary completion date: The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 17, 2018
P2, N=119, Completed, Sponsor: Chengdu PLA General Hospital
Trial primary completion date: Nov 2014 --> Sep 2017
- ||||||| Lupuzor (rigerimod) / ImmuPharma, Alora Pharma
Trial completion: A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jan 17, 2018
P3, N=200, Completed, Sponsor: ImmuPharma
Trial primary completion date: Nov 2014 --> Sep 2017 Active, not recruiting --> Completed
- | Enrollment change: Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases (clinicaltrials.gov) - Jan 16, 2018
P=N/A, N=200, Completed, Sponsor: Fondazione Italiana Sclerosi Multipla
Active, not recruiting --> Completed N=2000 --> 200
- | Trial completion, Enrollment change: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Jan 16, 2018
P3, N=38, Completed, Sponsor: University Hospital, Bordeaux
N=2000 --> 200 Recruiting --> Completed | N=80 --> 38
- | Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Enrollment change, Trial initiation date, Trial primary completion date: The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (clinicaltrials.gov) - Jan 16, 2018
P4, N=0, Withdrawn, Sponsor: Stanford University
Recruiting --> Completed | N=80 --> 38 N=30 --> 0 | Initiation date: Aug 2013 --> Jun 2014 | Trial primary completion date: Aug 2015 --> Dec 2016
- | febuxostat / Generic mfg.
Trial completion: The Effect of Uric Acid Lowering in Type 1 Diabetes (clinicaltrials.gov) - Jan 16, 2018
P4, N=73, Completed, Sponsor: University Health Network, Toronto
N=30 --> 0 | Initiation date: Aug 2013 --> Jun 2014 | Trial primary completion date: Aug 2015 --> Dec 2016 Recruiting --> Completed
- || Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed, Combination therapy, Monotherapy: EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis (clinicaltrials.gov) - Jan 12, 2018
P=N/A, N=200, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Trial primary completion date: Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes (clinicaltrials.gov) - Jan 12, 2018
P3, N=458, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Jan 2018
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment. (clinicaltrials.gov) - Jan 12, 2018
P=N/A, N=200, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2017 --> Jan 2018 Recruiting --> Active, not recruiting
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed: CONIFER: Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA (clinicaltrials.gov) - Jan 12, 2018
P=N/A, N=135, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Trial completion: Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients (clinicaltrials.gov) - Jan 11, 2018
P=N/A, N=108, Completed, Sponsor: American University of Beirut Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Trial completion, Trial primary completion date: Web-based Genetic Research on Lupus (clinicaltrials.gov) - Jan 10, 2018
P=N/A, N=5000, Completed, Sponsor: 23andMe, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Oct 2017
- | Trial completion, Phase classification, Enrollment change: Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation (clinicaltrials.gov) - Jan 10, 2018
P=N/A, N=14, Completed, Sponsor: University Hospital, Lille
Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Oct 2017 Recruiting --> Completed | Phase classification: P2 --> PN/A | N=19 --> 14
- | dalfampridine / Generic mfg.
Trial completion, Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Jan 9, 2018
P2, N=24, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed | Phase classification: P2 --> PN/A | N=19 --> 14 Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jan 2017
- | Phase classification, Trial termination, Trial primary completion date: Honey in Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Jan 9, 2018
P=N/A, N=30, Terminated, Sponsor: mamdouh abdulmaksoud abdulrhman
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jan 2017 Phase classification: P2 --> P=N/A | Suspended --> Terminated | Trial primary completion date: Jan 2017 --> Dec 2017; problem with the candidate (investigator)
- | Trial completion, Trial primary completion date: Periodontal Inflammation and Immunity in Preclinical Rheumatoid Arthritis (clinicaltrials.gov) - Jan 9, 2018
P=N/A, N=146, Completed, Sponsor: University of Colorado, Denver
Phase classification: P2 --> P=N/A | Suspended --> Terminated | Trial primary completion date: Jan 2017 --> Dec 2017; problem with the candidate (investigator) Recruiting --> Completed | Trial primary completion date: Jul 2018 --> Dec 2017
- Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Trial primary completion date: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP (clinicaltrials.gov) - Jan 9, 2018
P2, N=36, Recruiting, Sponsor: arGEN-X BVBA
Recruiting --> Completed | Trial primary completion date: Jul 2018 --> Dec 2017 Trial primary completion date: Nov 2017 --> Aug 2018
- | Trial primary completion date: Interferon ß-1b Treatment by Cyclical Administration (clinicaltrials.gov) - Jan 8, 2018
P2/3, N=60, Completed, Sponsor: S. Andrea Hospital
Trial primary completion date: Nov 2017 --> Aug 2018 Trial primary completion date: Feb 2011 --> Aug 2010
- bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Enrollment change, Trial primary completion date: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Jan 5, 2018
P2, N=10, Recruiting, Sponsor: Immune Pharmaceuticals
Trial primary completion date: Feb 2011 --> Aug 2010 N=15 --> 10 | Trial primary completion date: Mar 2017 --> Apr 2018
- | Biomarker, Trial primary completion date, Immunomodulating: The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients (clinicaltrials.gov) - Jan 5, 2018
P2, N=50, Recruiting, Sponsor: Tabriz University of Medical Sciences
N=15 --> 10 | Trial primary completion date: Mar 2017 --> Apr 2018 Trial primary completion date: Dec 2017 --> Aug 2018
- PEC-Direct (PEC-01) / Vertex
Enrollment closed: A Safety and Tolerability Study of VC-02 (clinicaltrials.gov) - Jan 5, 2018
P1, N=15, Active, not recruiting, Sponsor: ViaCyte
Trial primary completion date: Dec 2017 --> Aug 2018 Recruiting --> Active, not recruiting
- | Firdapse (amifampridine) / BioMarin, Catalyst Pharma
Trial primary completion date: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) (clinicaltrials.gov) - Jan 4, 2018
P3, N=38, Completed, Sponsor: Catalyst Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Jul 2016
- | Trial primary completion date, Discordant: DIAPO: Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity (clinicaltrials.gov) - Jan 3, 2018
P=N/A, N=200, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Trial primary completion date: Sep 2014 --> Jul 2016 Trial primary completion date: Feb 2017 --> Mar 2018
- | Trial completion: Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy (clinicaltrials.gov) - Jan 3, 2018
P=N/A, N=150, Completed, Sponsor: Vista Klinik
Trial primary completion date: Feb 2017 --> Mar 2018 Recruiting --> Completed
- ||| Trial completion: A Trial With Humanized TNF? Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects (clinicaltrials.gov) - Dec 27, 2017
P1, N=72, Completed, Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Recruiting --> Completed Recruiting --> Completed
- | Trial completion, Trial primary completion date: ELECTOR_I: Home Monitoring of Patients With Rheumatoid Arthritis - an eHealth Development Study (clinicaltrials.gov) - Dec 22, 2017
P=N/A, N=240, Completed, Sponsor: Henrik Gudbergsen
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017
- | Enrollment closed, Enrollment change: Reverse Transcriptase Inhibitors in AGS (clinicaltrials.gov) - Dec 21, 2017
P2, N=11, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017 Recruiting --> Active, not recruiting | N=24 --> 11
- | Enrollment closed, Trial primary completion date: Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis (clinicaltrials.gov) - Dec 20, 2017
P=N/A, N=168, Active, not recruiting, Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Recruiting --> Active, not recruiting | N=24 --> 11 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2018 --> Mar 2018
- | New trial: Pilot Diet Study for Multiple Sclerosis (clinicaltrials.gov) - Dec 20, 2017
P=N/A, N=36, Active, not recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- ||||| PF-04236921 / Pfizer
New P2 trial: Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus (clinicaltrials.gov) - Dec 20, 2017
P2, N=183, Completed, Sponsor: Pfizer
- | New trial: Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=38, Completed, Sponsor: Vastra Gotaland Region
- | Phase classification: An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=100, Completed, Sponsor: Medtronic Diabetes
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2018 --> Mar 2018 Phase classification: P3 --> P=N/A
- | Enrollment closed, Phase classification, Enrollment change, Trial primary completion date: Pilot Diet Study for Multiple Sclerosis (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=36, Active, not recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Phase classification: P3 --> P=N/A Recruiting --> Active, not recruiting | Phase classification: P1 --> PN/A | N=30 --> 36 | Trial primary completion date: Jan 2018 --> May 2018 | Recruiting --> Active, not recruiting | Phase classification: P1 --> PN/A | N=30 --> 36 | Trial primary completion date: Jan 2018 --> May 2018 | Recruiting --> Active, not recruiting | Phase classification: P1 --> PN/A | N=30 --> 36 | Trial primary completion date: Jan 2018 --> May 2018
- | Trial completion: Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=38, Completed, Sponsor: Vastra Gotaland Region
Recruiting --> Active, not recruiting | Phase classification: P1 --> PN/A | N=30 --> 36 | Trial primary completion date: Jan 2018 --> May 2018 | Recruiting --> Active, not recruiting | Phase classification: P1 --> PN/A | N=30 --> 36 | Trial primary completion date: Jan 2018 --> May 2018 | Recruiting --> Active, not recruiting | Phase classification: P1 --> PN/A | N=30 --> 36 | Trial primary completion date: Jan 2018 --> May 2018 Recruiting --> Completed
- | Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, HEOR, Patient reported outcomes: Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? (clinicaltrials.gov) - Dec 15, 2017
P=N/A, N=146, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Completed Recruiting --> Active, not recruiting
- | dapsone / Generic mfg.
Phase classification, Trial termination, Trial primary completion date: Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis (clinicaltrials.gov) - Dec 14, 2017
P4, N=1, Terminated, Sponsor: Vanderbilt University Medical Center
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P4 | Not yet recruiting --> Terminated | Trial primary completion date: Apr 2011 --> Mar 2012; poor enrollment and lack of funding
- | Enrollment closed: Evaluation of the EarEEG System for Detection of Hypoglycaemia-induced Changes in the EEG in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=20, Active, not recruiting, Sponsor: Odense University Hospital
Phase classification: P=N/A --> P4 | Not yet recruiting --> Terminated | Trial primary completion date: Apr 2011 --> Mar 2012; poor enrollment and lack of funding Recruiting --> Active, not recruiting
- ||||||| Hyrimoz (adalimumab biosimilar) / Novartis
Trial completion: ADMYRA: Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 12, 2017
P3, N=353, Completed, Sponsor: Sandoz
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| JNJ-55920839 / J&J
Enrollment open, Trial primary completion date: A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - Dec 12, 2017
P1, N=80, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Suspended --> Recruiting | Trial primary completion date: Dec 2017 --> Sep 2018
- |||| Olumiant (baricitinib) / Incyte, Eli Lilly
Trial completion: JAHH: A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Dec 12, 2017
P2, N=314, Completed, Sponsor: Eli Lilly and Company
Suspended --> Recruiting | Trial primary completion date: Dec 2017 --> Sep 2018 Active, not recruiting --> Completed
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone (clinicaltrials.gov) - Dec 12, 2017
P1, N=43, Completed, Sponsor: Adocia
Active, not recruiting --> Completed Recruiting --> Completed
- | BioChaperone Human Glucagon (recombinant human glucagon) / Adocia
Trial completion: A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone (clinicaltrials.gov) - Dec 12, 2017
P1, N=27, Completed, Sponsor: Adocia
Recruiting --> Completed Recruiting --> Completed
- | Trial initiation date: GENEVIR: Gene-virus Interactions Implicated in Type 1 Diabetes (clinicaltrials.gov) - Dec 8, 2017
P=N/A, N=1100, Not yet recruiting, Sponsor: Hospices Civils de Lyon
Recruiting --> Completed Initiation date: Sep 2017 --> Dec 2017
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab) (clinicaltrials.gov) - Dec 7, 2017
P=N/A, N=400, Completed, Sponsor: Hoffmann-La Roche
Initiation date: Sep 2017 --> Dec 2017 Recruiting --> Completed
- | Trial completion, Trial primary completion date: MS-CARE: Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study (clinicaltrials.gov) - Dec 6, 2017
P=N/A, N=195, Completed, Sponsor: University of Washington
Recruiting --> Completed Enrolling by invitation --> Completed | Trial primary completion date: Oct 2016 --> Apr 2017
- elezanumab (ABT-555) / AbbVie
Enrollment closed, Enrollment change: A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Dec 5, 2017
P1, N=20, Active, not recruiting, Sponsor: AbbVie
Enrolling by invitation --> Completed | Trial primary completion date: Oct 2016 --> Apr 2017 Recruiting --> Active, not recruiting | N=35 --> 20
- | Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: Niclosamide With Etanercept in Rheumatoid Arthritis (clinicaltrials.gov) - Dec 5, 2017
P1/2, N=110, Recruiting, Sponsor: Faiq Gorial
Recruiting --> Active, not recruiting | N=35 --> 20 Trial primary completion date: Apr 2019 --> Apr 2018
- | Enrollment open: Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment (clinicaltrials.gov) - Dec 5, 2017
P=N/A, N=112, Recruiting, Sponsor: Samsung Medical Center
Trial primary completion date: Apr 2019 --> Apr 2018 Not yet recruiting --> Recruiting
- Enrollment change, Trial primary completion date: A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques (clinicaltrials.gov) - Dec 4, 2017
P1, N=10, Terminated, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=13 --> 10 | Trial primary completion date: Jun 2016 --> Oct 2016
- ||||||| CHS-0214 (etanercept biosimilar) / Coherus Biosci
Trial completion: A Long Term Safety Extension Study (CHS-0214-05) (clinicaltrials.gov) - Dec 2, 2017
P3, N=359, Completed, Sponsor: Coherus Biosciences, Inc.
N=13 --> 10 | Trial primary completion date: Jun 2016 --> Oct 2016 Active, not recruiting --> Completed